PE20252396A1 - Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion - Google Patents

Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion

Info

Publication number
PE20252396A1
PE20252396A1 PE2025001666A PE2025001666A PE20252396A1 PE 20252396 A1 PE20252396 A1 PE 20252396A1 PE 2025001666 A PE2025001666 A PE 2025001666A PE 2025001666 A PE2025001666 A PE 2025001666A PE 20252396 A1 PE20252396 A1 PE 20252396A1
Authority
PE
Peru
Prior art keywords
composition
same
injectable composition
preparing
pharmaceutical formulation
Prior art date
Application number
PE2025001666A
Other languages
English (en)
Spanish (es)
Inventor
Aeri Kim
Jungmin Yun
John Kim
Original Assignee
Jeil Pharmaceutical Co Ltd
Onconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd, Onconic Therapeutics Inc filed Critical Jeil Pharmaceutical Co Ltd
Publication of PE20252396A1 publication Critical patent/PE20252396A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2025001666A 2023-02-01 2024-01-31 Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion PE20252396A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230013947 2023-02-01
PCT/IB2024/050869 WO2024161316A1 (en) 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Publications (1)

Publication Number Publication Date
PE20252396A1 true PE20252396A1 (es) 2025-10-10

Family

ID=92024104

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025001666A PE20252396A1 (es) 2023-02-01 2024-01-31 Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion

Country Status (15)

Country Link
EP (1) EP4658244A1 (https=)
JP (1) JP2026505092A (https=)
KR (1) KR20240121186A (https=)
CN (1) CN118415999A (https=)
AR (1) AR131668A1 (https=)
AU (1) AU2024215883A1 (https=)
CL (1) CL2025002270A1 (https=)
CO (1) CO2025011347A2 (https=)
DO (1) DOP2025000185A (https=)
IL (1) IL322431A (https=)
JO (1) JOP20250189A1 (https=)
MX (1) MX2025008735A (https=)
PE (1) PE20252396A1 (https=)
TW (1) TW202432120A (https=)
WO (1) WO2024161316A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120827558A (zh) * 2024-04-19 2025-10-24 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
AR051041A1 (es) * 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101777971B1 (ko) * 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
AR131668A1 (es) 2025-04-16
CO2025011347A2 (es) 2025-09-18
IL322431A (en) 2025-09-01
KR20240121186A (ko) 2024-08-08
AU2024215883A1 (en) 2025-07-31
JP2026505092A (ja) 2026-02-10
CN118415999A (zh) 2024-08-02
MX2025008735A (es) 2025-11-03
DOP2025000185A (es) 2026-02-15
EP4658244A1 (en) 2025-12-10
CL2025002270A1 (es) 2025-10-03
TW202432120A (zh) 2024-08-16
JOP20250189A1 (ar) 2025-07-28
WO2024161316A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
AR029462A1 (es) Derivados del acido picolinico, procedimiento para prepararlos y composiciones formuladas con dichos derivados como agente activo, procedimientos preventivos o curativos contra hongos fitopatogenos, metodos preventivos o de tratamiento de la madera para la construccion utilizando dichos compuestos y
RU2018119295A (ru) Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
MX2019004238A (es) Composiciones farmaceuticas liofilizadas para suministro vaginal.
JP2012180381A5 (https=)
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
UY28271A1 (es) Compuestos químicos
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
ECSP055788A (es) Sistema de suministro de fármacos
CO6551707A2 (es) Procedimiento para la preparaciçon de {4.6-diamino-2[1-2(2-fluorobencil)-1h- pirazolo [3.4-b]piridin -3-il] pirimidin -5-il} carbamato de metilo y su purificación para el uso como principio activo farmacéutico
AR083249A1 (es) Combinaciones sinergicas de triazoles, estrobirulinas y benzimidazoles, usos, formulaciones, procedimientos de produccion y aplicaciones utilizando las mismas
AR048718A1 (es) Uso de formulaciones de meloxicam en medicina veterinaria
PE20252396A1 (es) Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion
EP4516318A3 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
ES2527890T3 (es) Formulaciones de pastas homogéneas
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica